Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling Meeting Abstract
| Authors: | Lopez, P. G.; Felip, E.; Delord, J. P.; Paz-Ares, L.; Grilley-Olson, J. E.; Gordon, M. S.; Barisal, F.; Arkenau, H. T.; Lara, P.; Paik, P. K.; Morgansztern, D.; Gadgeel, S. M.; Reckamp, K. L.; Bertino, E. M.; Orlov, S.; Levchenko, E.; Delgado, I.; Perez, J. M. T.; Moran, T.; Lassen, U. N. |
| Abstract Title: | Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling |
| Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2014 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358613202200 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.15_suppl.tps8120 |
| Notes: | Meeting Abstract: TPS8120 -- Source: Wos |
